<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148937</url>
  </required_header>
  <id_info>
    <org_study_id>17504</org_study_id>
    <secondary_id>J2I-MC-JZMA</secondary_id>
    <secondary_id>2019-003270-64</secondary_id>
    <secondary_id>Keynote A57</secondary_id>
    <nct_id>NCT04148937</nct_id>
  </id_info>
  <brief_title>A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer</brief_title>
  <official_title>A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination
      with pembrolizumab is safe and effective in participants with advanced cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>Number of Participants with DLT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3475070</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 7 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: AUC of LY3475070</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LY3475070</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 7 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: Cmax of LY3475070</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of LY3475070 in Combination with Pembrolizumab</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 7 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: AUC of LY3475070 in Combination with Pembrolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of LY3475070 in Combination with Pembrolizumab</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 7 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: Cmax of LY3475070 in Combination with Pembrolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Disease Progression or Death (Estimated at up to 2 Years)</time_frame>
    <description>ORR: Percentage of Participants with CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of CR, PR, and Stable Disease</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated at up to 2 Years)</time_frame>
    <description>DCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated at up to 2 Years)</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A LY3475070</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3475070 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B LY3475070 + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3475070 administered orally and pembrolizumab administered intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C1 LY3475070 + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3475070 administered orally and pembrolizumab administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C2 LY3475070</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3475070 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D1 LY3475070 + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3475070 administered orally and pembrolizumab administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D2 LY3475070</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3475070 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E LY3475070 + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3475070 administered orally and pembrolizumab administered IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3475070</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Cohort A LY3475070</arm_group_label>
    <arm_group_label>Cohort B LY3475070 + Pembrolizumab</arm_group_label>
    <arm_group_label>Cohort C1 LY3475070 + Pembrolizumab</arm_group_label>
    <arm_group_label>Cohort C2 LY3475070</arm_group_label>
    <arm_group_label>Cohort D1 LY3475070 + Pembrolizumab</arm_group_label>
    <arm_group_label>Cohort D2 LY3475070</arm_group_label>
    <arm_group_label>Cohort E LY3475070 + Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Cohort B LY3475070 + Pembrolizumab</arm_group_label>
    <arm_group_label>Cohort C1 LY3475070 + Pembrolizumab</arm_group_label>
    <arm_group_label>Cohort D1 LY3475070 + Pembrolizumab</arm_group_label>
    <arm_group_label>Cohort E LY3475070 + Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have certain types of cancer such as breast cancer, pancreatic
             cancer, lung cancer, kidney cancer, skin cancer (melanoma), prostate cancer, and
             ovarian cancer

          -  Participants must have stopped other forms of treatment for the cancer

          -  In the expansion cohorts participants must be able and willing to provide a sample of
             the tumor before beginning treatment and a sample during the treatment. For certain
             tumor types, the result of a test on the tumor sample may exclude the participant from
             the study

          -  Participants must not be pregnant, and must agree to use birth control

          -  Participants must have progressed through or be intolerant to therapies with known
             clinical benefit

        Exclusion Criteria:

          -  Participants must not have a current untreated tuberculosis, lung disease, heart
             disease, uncontrolled HIV, autoimmune disease, active hepatitis B or C virus infection
             or using corticosteroids

          -  Participant must not have cancer that has spread to the brain

          -  Participant must not have received a vaccine within the last 30 days

          -  Participant must not have had bowel obstruction within the last 6 months, or
             intestinal surgery

          -  Participant must not have an infection that is currently being treated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>310-967-2700</phone>
    </contact>
    <investigator>
      <last_name>Heather L McArthur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of California, Davis- Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>916-734-3735</phone>
    </contact>
    <investigator>
      <last_name>Karen P Kelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthOne</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>720-754-2610</phone>
    </contact>
    <investigator>
      <last_name>Shiraj Sen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists ORLANDO/DDU</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>941-377-9993</phone>
    </contact>
    <investigator>
      <last_name>Shekeab Jauhari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Midwest Cancer and Hematology Centers of W Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manish Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>314-747-7510</phone>
    </contact>
    <investigator>
      <last_name>Mateusz Opyrchal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>216-445-5670</phone>
    </contact>
    <investigator>
      <last_name>Dale Shepard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>SMO Sarah Cannon Research Inst.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-745-6754</phone>
    </contact>
    <investigator>
      <last_name>Sarina A Piha-Paul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>61385595000</phone>
    </contact>
    <investigator>
      <last_name>Sherene Loi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Simon Pacey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Center</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0141 301 7116</phone>
    </contact>
    <investigator>
      <last_name>Jeff Evans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4 BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>441614463000</phone>
    </contact>
    <investigator>
      <last_name>Louise Carter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+442086426011</phone>
    </contact>
    <investigator>
      <last_name>Johann De Bono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/advanced-cancer/JZMA#?postal=</url>
    <description>A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer</description>
  </link>
  <verification_date>July 15, 2020</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple Negative Breast Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Renal Cell Carcinoma, Clear Cell</keyword>
  <keyword>Cutaneous Melanoma</keyword>
  <keyword>Castrate Resistant Prostate Cancer</keyword>
  <keyword>Epithelial Ovarian Cancer</keyword>
  <keyword>Metastatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

